FITC Rat Anti-Mouse PD-1 (CD279) Antibody (S-R496)
FITC Rat Anti-Mouse PD-1 (CD279) Antibody (S-R496)
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | PD-1 (CD279) |
| Synonyms | Programmed cell death protein 1; Protein PD-1; mPD-1; Pdcd1 |
| Location | Cell membrane |
| Accession | Q02242 |
| Clone Number | S-R496 |
| Antibody Type | Rat mAb |
| Isotype | IgG2a |
| Application | FCM |
| Reactivity | Ms |
| Purification | Protein G |
| Conjugation | FITC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5 μl per million cells in 100μl volume |
Background
Programmed cell death protein 1 (PD-1), also known as CD279, is a type I transmembrane protein and a member of the CD28 immunoglobulin superfamily, encoded by the _PDCD1_ gene. It is primarily expressed on the surface of various immune cells, including T cells, B cells, macrophages, dendritic cells, and natural killer cells. PD-1 plays a crucial role in regulating immune responses by binding to its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), which are expressed on antigen-presenting cells and tumor cells. When PD-1 interacts with its ligands, it triggers inhibitory signals that downregulate T cell activity, preventing excessive immune responses and promoting self-tolerance. However, this pathway can also be exploited by cancer cells to evade immune surveillance, leading to tumor progression. As a result, PD-1 has become a key target in cancer immunotherapy, with several anti-PD-1 antibodies approved for treating various cancers, achieving significant and durable efficacy in some patients.
